A review of bevacizumab in the treatment of malignant pleural mesothelioma. (December 2017)

• Record Type: Journal Article
• Authors: Brosseau, Solenn; Assoun, Sandra; Naltet, Charles; Steinmetz, Christelle; Gounant, Valérie; Zalcman, Gérard
• Is Part Of: Future oncology. Volume 13:Number 28(2017)
• Page Start: 2537
• Page End: 2546
• Publication Date: 2017-12
• Subjects: angiogenesis inhibitor -- bevacizumab -- malignant pleural mesothelioma; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2017-0307
• Languages: English
• ISSNs: 1479-6694

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis. Systemic chemotherapy is the primary treatment modality for the majority of patients. VEGF plays a key mitogen for MPM cells physiopathology. Bevacizumab, a monoclonal anti-VEGF antibody, was a rational approach to be tested in MPM. Based on the results of the Phase III IFCT-0701 mesothelioma avastin cisplatin pemetrexed study, cisplatin-pemetrexed-bevacizumab is now the accepted standard in France. The National Comprehensive Cancer Network guidelines have also included this combination as an option for standard front-line therapy. This review summarized the efficacy and safety data of bevacizumab in the treatment of patients with MPM.